28.99
+8.01%
Close of 9 Nov 2026, in USD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Viking Therapeutics
From its filings with the US Securities and Exchange Commission
Viking Therapeutics is based in San Diego, California and is incorporated in Delaware. Its shares trade on Nasdaq under the ticker VKTX. The SEC classifies its business as pharmaceutical preparations. In the fiscal year to 31 December 2025, it reported revenue of $0 and a net loss of $359.6m. At that date it held total assets of $715.7m and shareholders' equity of $639.1m.
We are a clinical-stage biopharmaceutical company focused on the development of novel, first-in-class or best-in-class therapies for metabolic and endocrine disorders.
In January 2022, we announced the initiation of a Phase 1 single ascending dose, or SAD, and multiple ascending dose, or MAD, clinical trial of VK2735, a novel dual agonist of the glucagon-like peptide 1, or GLP-1, and glucose-dependent insulinotropic polypeptide, or GIP, receptors. VK2735 is being developed in both oral and subcutaneous formulations for the potential treatment of various metabolic disorders such as obesity.
In March 2023, we announced the completion of the Phase 1 trial. The study was a randomized, double-blind, placebo-controlled, SAD and MAD study in healthy adults. The primary objectives of the study included evaluation of the safety and tolerability of single and multiple doses of VK2735 delivered subcutaneously and the identification of VK2735 doses suitable for further clinical development. Study investigators also evaluated the pharmacokinetics of single and multiple doses of VK2735. Based upon the results from this Phase 1 study, in September 2023, we initiated the VENTURE study, a Phase 2 clinical trial of VK2735 in patients with obesity.
Quoted from its 10-K, filed 11 Feb 2026. Read the filing on SEC.gov ↗
Company facts
- Sector
- Health Care
- Industry
- Biotechnology
- Listed since
- 29 Apr 2015
- Employees
- 53
- Website
- vikingtherapeutics.com ↗
- Head office
- 9920 PACIFIC HEIGHTS BLVD, SUITE 500, SAN DIEGO, CA
- Incorporated in
- DE
- Classification
- Pharmaceutical Preparations
- Filer status
- Large accelerated filer
Leadership
Pay as last reported
- Dr. Lawson MacartneyIndependent Chairman of the Board$488,647
- Dr. Brian LianPresident, Chief Executive Officer, Director, since 2012$14.3m
- Mr. Greg ZanteChief Financial Officer$4.7m
- Ms. Marianne ManciniChief Operating Officer$4.7m
- Mr. Neil AubuchonChief Commercial Officer
- Mr. Matthew FoehrIndependent Director$433,347
- Dr. S. Kathy RouanIndependent Director$443,347
- Mr. Charles RowlandIndependent Director$458,347
- Mr. J. Matthew SingletonIndependent Director$460,847
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 44
- Environment
- 43
- Social
- 70
- Governance
- 17
- Carbon reduction policy
- No
- Human rights policy
- No
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Viking Therapeutics Inc has several strengths that contribute to its competitive advantage:
Weaknesses
- Despite its strengths, Viking Therapeutics Inc also faces certain weaknesses:
Opportunities
- Viking Therapeutics Inc can capitalize on the following opportunities:
Threats
- Viking Therapeutics Inc faces several threats that could impact its business and growth:
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.